Travere Therapeutics

Orphan Technologies Ltd. is a clinical-stage biopharmaceutical company based in Rapperswil, Switzerland, focused on developing innovative therapies for patients with rare disorders, particularly classical homocystinuria (HCU). Incorporated in 2016, the company aims to alleviate the challenges faced by individuals suffering from HCU, a genetic condition that leads to serious cardiovascular, skeletal, neurologic, and ophthalmologic complications. Its lead drug candidate, OT-58, is an optimized enzyme replacement therapy designed to effectively lower homocysteine levels through a targeted mechanism. This therapy not only addresses the symptoms of classical homocystinuria but also holds potential for therapeutic applications in other related diseases. Orphan Technologies operates as a subsidiary of Travere Therapeutics, Inc.

Manchester Pharmaceuticals is a specialty pharmaceutical company dedicated to the identification, development, FDA approval, and commercialization of innovative therapeutic modalities aimed at addressing the unique needs of patients with ultra-rare diseases. By focusing on rare diseases, the company seeks to provide effective treatment options for conditions that often lack adequate therapies, thereby improving patient outcomes in this underserved segment of healthcare.